Jason W. H. Wong

TL;DR: DOT1L is identified as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis, and DOT1L inhibitors are characterized as novel anticancer agents against MYCN-amplified Neuroblastoma cells.

TL;DR: The N-terminus (through residue 36) of calmodulin is shown to lie in closer proximity to the melittin helix than its C-terminal counterpart (residues 127–148) based upon the protection levels measured at reactive residues within these segments of the protein.

TL;DR: A small organoarsenical compound, 4-(N-(S-glutathionylacetylamino)phenylarsonous acid, that rapidly accumulates in the cytosol of dying cells coincident with loss of plasma membrane integrity, should enable the imaging of cell death in most experimental settings.

TL;DR: It is reported that skin cancers exhibit a highly specific asymmetric mutation pattern within CTCF motifs attributable to ultraviolet irradiation and differential nucleotide excision repair (NER), suggesting a role for cohesin in stabilizing C TCF-DNA binding and impairing NER.

TL;DR: JMJD6 is identified as a neuroblastoma tumorigenesis factor, and the combination therapy with the CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistically reduces JMJD6, E2F2, N- myc, c-Myc expression, induces apoptosis in vitro and leads to neuroblastomas tumor regression in mice, which are significantly reversed by forced JM JD6 over-expression.